09:01 AM EST, 11/05/2025 (MT Newswires) -- Appili Therapeutics ( APLIF ) , a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced Wednesday a non-brokered private placement for about $750,000.

The company said the offering will be comprised of the issuance of up to about 30-million units at $0.025 apiece. Each unit will consist of one Class A common share and one-half of one three-year purchase warrant and each warrant, subject to receipt of shareholder approval, will entitle the holder to buy a share for $0.05.

Proceeds will be used primarily for working capital needs and to fund the development of certain of its product candidates. Closing of the private placement is expected in November.

Shares of the company closed down 16% to $0.025 on Tuesday on the Toronto Stock Exchange.